Global Urinary Tract Infection (UTI) Market Growth (Status and Outlook) 2025-2031

According to this study, the global Urinary Tract Infection (UTI) market size will reach US$ million by 2031.

Urinary tract infection (UTI), is an infectious disease caused by the growth and proliferation of pathogens in the urinary tract.Pathogens may include bacteria, mycoplasma, chlamydia, viruses, etc.Urinary tract infection is the second most common infectious disease after respiratory tract infection.Shock deaths from urinary tract infections were the third leading cause of death.

United States market for Urinary Tract Infection (UTI) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Urinary Tract Infection (UTI) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Urinary Tract Infection (UTI) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Urinary Tract Infection (UTI) players cover Novartis AG, GlaxoSmithKline, Dr. Reddy’s Laboratories Ltd.,, Pfizer, Roche, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Urinary Tract Infection (UTI) Industry Forecast” looks at past sales and reviews total world Urinary Tract Infection (UTI) sales in 2024, providing a comprehensive analysis by region and market sector of projected Urinary Tract Infection (UTI) sales for 2025 through 2031. With Urinary Tract Infection (UTI) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Urinary Tract Infection (UTI) industry.

This Insight Report provides a comprehensive analysis of the global Urinary Tract Infection (UTI) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Urinary Tract Infection (UTI) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Urinary Tract Infection (UTI) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Urinary Tract Infection (UTI) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Urinary Tract Infection (UTI).

This report presents a comprehensive overview, market shares, and growth opportunities of Urinary Tract Infection (UTI) market by product type, application, key players and key regions and countries.

Segmentation by Type:
By Site of Infection
By Clinical Symptoms
By Presence of Urinary Tract Abnormalities

Segmentation by Application:
Hospitals
Clinic
Self-administered
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis AG
GlaxoSmithKline
Dr. Reddy’s Laboratories Ltd.,
Pfizer
Roche
AstraZeneca,
Cipla
Johnson & Johnson
Bayer AG
Teva Pharmaceutical Industries
Boehringer Ingelheim
Sanofi
Lily
Abbott
JinShuiBao
Shanghai Sine Pharmaceutical Laboratories (Shanghai Pharmaceuticals Holding)
Sinopharm
Borui Medicine
Zhejiang Xianju Pharmaceutical
Sichuan Guorui Pharmaceutical
Hengrui Pharmaceutical

Please note: The report will take approximately 2 business days to prepare and deliver. Show more